Akademik Veri Yönetim Sistemi
ISTANBUL JOURNAL OF PHARMACY, sa.3, ss.359-367, 2024 (ESCI)
Background and Aims: Sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, has been shown to have beneficial effects on the diabetic heart. Beta-adrenoceptor (beta-AR)-mediated responses are impaired in diabetes. Our aim was to investigate the impact of sitagliptin on the diabetic rat heart in terms of beta-AR-mediated responsiveness. In addition, we examined the expression of proteins associated with diastolic dysfunction and endoplasmic reticulum (ER) stress, as well as proteins involved in the beta-AR signalling pathway. Methods: Eight-week-old Sprague-Dawley rats were divided into control, diabetic, and sitagliptin-treated (10 mg/kg/day for 4 weeks) diabetic groups. Type 1 diabetes was induced by intraperitoneal injection of streptozotocin (STZ). Throughout the treatment period, the rats received sitagliptin orally. Cardiac beta-AR responsiveness was assessed using in vitro papillary muscle experiments with a nonselective beta-AR agonist, isoprenaline, and in vitro Langendorff heart preparation experiments with a beta 3-AR selective agonist CL 316,243. Western blot experiments were conducted to assess the protein expression of SERCA2a, GRP78, beta 3-AR, eNOS, and p-eNOS. Results: Sitagliptin did not reduce blood glucose levels or reverse weight loss in diabetic rats. However, it improved the heart weight to body weight ratio, indicating a reduction in cardiac hypertrophy. Sitagliptin did not correct the isoprenaline-induced contractile response in the diabetic group, nor did it alter the beta 3-AR mediated relaxation. Sitagliptin treatment also did not improve the downregulation of SERCA2a or the upregulation of GRP78. However, it reduced the upregulation of beta 3-AR. The protein expression of eNOS and the ratio of p-eNOS to eNOS were similar among the groups. Conclusion: This study indicates that sitagliptin treatment did not improve isoprenaline-mediated contractile responses or affect beta 3-AR-mediated relaxation in the diabetic heart. However, the observed increase in beta 3-AR protein expression in the diabetic heart treated with sitagliptin indicated a potential differential effect of the drug on this pathway compared to the beta 1-AR signalling pathway. Further studies are needed to elucidate the precise mechanisms by which sitagliptin influences beta 3-AR-mediated pathways.